Welcome
Support Centre
21 March 2013 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   news
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes
statistics

[ Print-friendly version ]
A randomised trial of intravesical irrigation in superficial bladder cancer followed by treatment with epodyl or mitomycin C at the time of first recurrence
ISRCTN ISRCTN88118697
DOI 10.1186/ISRCTN88118697
ClinicalTrials.gov identifier
EudraCT number
Public title A randomised trial of intravesical irrigation in superficial bladder cancer followed by treatment with epodyl or mitomycin C at the time of first recurrence
Scientific title
Acronym N/A
Serial number at source BS04
Study hypothesis 1. To detect the reduction, if any, of recurrence following irrigation of the bladder with glycine following complete resection of newly diagnosed bladder cancer
2. To compare the effect of Mitomycin-C against Epodyl in patients who develop recurrent superficial tumour following the initial transurethral resection in preventing further recurrence
Lay summary Not provided at time of registration
Ethics approval Not provided at time of registration
Study design Randomised controlled trial
Countries of recruitment United Kingdom
Disease/condition/study domain Bladder cancer
Participants - inclusion criteria 1. Newly diagnosed superficial bladder cancer suitable for complete endoscopic resection
2. Transitional cell carcinoma limited to the bladder, no evidence of carcinoma in the upper tracts
3. World Health Organisation (WHO) performance status 0-2
4. Expected survival at least 3 years
5. White count greater than 3 x 10^9/L and platelets greater than 100 x 10^9/L
6. No untreated urinary tract infection
Participants - exclusion criteria Not provided at time of registration
Anticipated start date 01/07/1987
Anticipated end date 01/12/1995
Status of trial Completed
Patient information material Not available in web format, please use the contact details below to request a patient information sheet
Target number of participants 1000
Interventions Epodyl or mitomycin C
Follow-up: 3 monthly for 1st year, 6 monthly for 2nd year, annually thereafter.
Primary outcome measure(s) Recurrence free survival
Secondary outcome measure(s) Not provided at time of registration
Sources of funding Medical Research Council (MRC) (UK)
Trial website
Publications
Contact name Dr  Danielle  Andrews
  Address MRC Clinical Trials Unit
222 Euston Road
  City/town London
  Zip/Postcode NW1 2DA
  Country United Kingdom
  Email
Sponsor Medical Research Council (MRC) (UK)
  Address 20 Park Crescent
  City/town London
  Zip/Postcode W1B 1AL
  Country United Kingdom
  Tel +44 (0)20 7636 5422
  Fax +44 (0)20 7436 6179
  Email clinical.trial@headoffice.mrc.ac.uk
  Sponsor website: http://www.mrc.ac.uk
Date applied 13/03/2001
Last edited 06/06/2012
Date ISRCTN assigned 13/03/2001
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2013 ISRCTN unless otherwise stated.